Document Detail


Impact of different hormone replacement therapy regimens on the size of myoma uteri in postmenopausal period: tibolone versus transdermal hormonal replacement system.
MedLine Citation:
PMID:  12161049     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVES: To assess the effect of different hormone replacement therapy regimens on myoma uteri in postmenopausal period. METHODS: Totally 46 patients with 60 myomas attending to Department of Obstetrics and Gynecology, Akdeniz University School of Medicine between May 2000 and March 2001 because of postmenopausal symptoms and having myoma uteri were included in this study. These patients were randomized for tibolone and transdermal hormonal replacement therapy system. The patients who were taking hormonal replacement therapy, discontinued the treatments and lost for follow-up were excluded from the study. Impact of the treatments on the size of myoma uteri was evaluated 6 months after starting the therapy. Size of myomas were evaluated by transvaginal sonography before and 6 months after onset of the treatment. RESULTS: Mean age was 57.3 (50-70) and mean gravida 3.6 (1-6) for all the patients. Although, increase in the size of myoma uteri was frequent in transdermal HRT, it was not statistically significant. CONCLUSION: There are no statistical significant differences between tibolone and transdermal hormonal replacement therapy regimens in respect to increase in the size of myoma uteri.
Authors:
T Simsek; C Karakus; B Trak
Related Documents :
22323849 - Vestibular and stabilometric findings in whiplash injury and minor head trauma.
24499959 - Lateral spread response monitoring during microvascular decompression for hemifacial sp...
21957799 - The effect of palliative daycare on hope: a comparison of daycare patients with two con...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial    
Journal Detail:
Title:  Maturitas     Volume:  42     ISSN:  0378-5122     ISO Abbreviation:  Maturitas     Publication Date:  2002 Jul 
Date Detail:
Created Date:  2002-08-05     Completed Date:  2003-06-10     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7807333     Medline TA:  Maturitas     Country:  Ireland    
Other Details:
Languages:  eng     Pagination:  243-6     Citation Subset:  IM    
Affiliation:
Department of Obstetrics and Gynecology, Akdeniz University School of Medicine, Antalya, Turkey. simsek@med.akdeniz.edu.tr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Cutaneous
Aged
Antineoplastic Agents, Hormonal / administration & dosage*
Endometrial Neoplasms / pathology
Estradiol / administration & dosage
Estrogen Replacement Therapy*
Female
Humans
Leiomyoma / drug therapy*,  pathology,  ultrasonography
Middle Aged
Norethindrone / administration & dosage,  analogs & derivatives*
Norpregnenes / administration & dosage*
Polyps / pathology
Postmenopause
Progesterone Congeners / administration & dosage
Uterine Hemorrhage / chemically induced
Uterine Neoplasms / drug therapy*,  pathology,  ultrasonography
Chemical
Reg. No./Substance:
0/Antineoplastic Agents, Hormonal; 0/Norpregnenes; 0/Progesterone Congeners; 38673-38-0/norethindrone acetate; 50-28-2/Estradiol; 5630-53-5/tibolone; 68-22-4/Norethindrone

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Effect of postmenopausal oestradiol and dydrogesterone therapy on lipoproteins and insulin sensitivi...
Next Document:  The effect of tibolone on endometrial IGF-1 and IGFBP-1 levels in ovariectomized rats.